Pharmaceutical Competitive Intelligence Excellence:
Optimizing Data Collection within Approved Guidelines
STUDY OVERVIEW
This benchmarking study was conducted to understand how U.S. pharmaceutical and biotechnology organizations can optimize their CI operations while working within defined guidelines. The research examined a number of areas, including CI information sources and what is being collected. In addition, the study looked at how CI groups work with legal groups to develop standard operating procedures for data collection that are in the best interests of the organization as a whole and to maximize the CI department’s ability to deliver results. Managers and executives in CI and CI-related groups can use this report to compare critical elements of their operations with those of leading firms.
KEY TOPICS
- Optimizing Data Collection - People, Processes & Practices
- Development & Examples of CI Guidelines
- Managing Expectations
- Rapid Response Teams
- Building a Successful CI Function
KEY METRICS
- Total Number of Marketed Brands Supported
- Number of Blockbuster Brands Supported
- Number of Pipeline Products Supported
- Number of Competitive Intelligence Full-Time Employees (FTEs)
- Effectiveness of Primary and Secondary Data Sources
- Effectiveness of Internal and External CI Data Collection Sources
- Effectiveness of Sources for Types of Information
- Formal Policies/Guidelines Governing CI Performance and Scope
- Functions Responsible for Guidelines Governing CI Operations
- Information Included in CI Guidelines
- Assessment of Guideline Impact on CI Function Productivity
- CI Guidelines Training
- CI Activities Ethical Assessments
- Rapid Response Team Utilization
METHODOLOGY
| This research was based on benchmark survey data from 24 executives from both large and small pharmaceutical and biotechnology companies. Executives from eight companies participated in the interview portion of the research. |
Sales and Marketing > Marketing Management
d
Industries Profiled:
Biotech; Pharmaceutical; Health Care; Manufacturing; Diagnostic
Companies Profiled:
Alcon Laboratories; Sanofi-aventis; Wyeth Pharmaceuticals; Takeda Pharmaceuticals; Pfizer; Roche; Merck; Eli Lilly; Baxter Healthcare; Amgen; Vertex Pharmaceuticals; Theratechnologies; TAP; Stiefel; Shire; PDL; King Pharmaceuticals; Indegene Lifesystems; Human Genome Sciences; Ethicon Endo-Surgery Inc.; EMD Serono; ConjuChem Biotechnologies; Centocor; Inc.; Biogen Idec
Related Research:
Brand Management Excellence Services
 |
The importance of brand management has led to the emergence of an increasingly sophisticated system to adequately coordinate, communicate and execute the critical activities that propagate and sustain brand growth... (ID SMS-3)
Companies Profiled: 3M Pharmaceuticals, aaiPharma, Abbott Laboratories,
Solvay America; Sanofi-Synthelabo Inc.; Pfizer; Ortho Biotech; Organon; Novartis; Eli Lilly and Company; IVAX; Baxter Healthcare; Bayer
, more ...
Price: $29995.00 Free Excerpt Available
| |
Educating The Market: Creating Value Through Support of Continuing Medical Education
|
STUDY OVERVIEW
With limited information on actual return on investment for expenditures toward support of Continuing Medical Education activities, Pharmaceutical and Biotechnology companies are anxious to understand the value of CME support and strategies for ensuring investments provide appropriate impact on healthcare practitioner behaviors and patient outcomes... (ID PSM-223)
Companies Profiled: Alcon Laboratories, Sanofi-aventis, Wyeth Pharmaceuticals, TAP, more ...
Price: $5995.00 Free Excerpt Available
| |
|